LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

44.53 -3.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.32

Max

45.96

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+19.27% upside

Turustatistika
By TradingEconomics
Turukapital	331M 3.6B
Eelmine avamishind	47.64
Eelmine sulgemishind	44.53

Uudiste sentiment

By Acuity

50%

156 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. dets 2025, 15:21 UTC

Tulu

Correction to Home Depot Outlook Headline on Dec. 9

23. dets 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23. dets 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 21:21 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Hold Deposit in Escrow

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23. dets 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23. dets 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23. dets 2025, 19:13 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23. dets 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23. dets 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23. dets 2025, 17:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23. dets 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23. dets 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23. dets 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank: Closing Expected Around Mid-January

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23. dets 2025, 16:02 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23. dets 2025, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Receives Green Light for Acquisition in Poland

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica Doesn't Set Out Financial Details of Divestment

23. dets 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Deal Will Allow Focus on Core Markets

23. dets 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23. dets 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

19.27% tõus

12 kuu keskmine prognoos

Keskmine 54.96 USD 19.27%

Kõrge 65 USD

Madal 44 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

156 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.